|
Commitments and Contingencies - Additional Information (Detail)
|
3 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2014
USD ($)
|
Mar. 31, 2013
USD ($)
|
Mar. 31, 2014
Excess lease facility [Member]
USD ($)
|
Dec. 31, 2013
Excess lease facility [Member]
USD ($)
|
Mar. 31, 2014
Other Long Term Assets [Member]
USD ($)
|
Mar. 31, 2014
Isis Pharmaceuticals Inc. and University of British Columbia [Member]
USD ($)
|
Mar. 31, 2014
Isis Pharmaceuticals Inc. and University of British Columbia [Member]
Collaboration arrangement [Member]
CAD
|
Mar. 31, 2014
Isis Pharmaceuticals Inc. [Member]
Collaboration arrangement [Member]
USD ($)
|
Dec. 31, 2009
Teva Pharmaceutical Industries Ltd. [Member]
Collaboration arrangement [Member]
USD ($)
|
Mar. 31, 2014
Teva Pharmaceutical Industries Ltd. [Member]
Collaboration arrangement [Member]
USD ($)
|
|
| Other Commitments [Line Items] | ||||||||||
| Collaboration agreement aggregate amount | $ 50,000,000 | |||||||||
| Maximum amount receivable | 370,000,000 | |||||||||
| Equity investment | 10,000,000 | |||||||||
| Direct and indirect costs incurred | 30,000,000 | |||||||||
| Milestone payments | 1,600,000 | 7,750,000 | ||||||||
| Amount receivable by Isis from TEVA as a milestone payment | 30.00% | |||||||||
| Percentage of un-spent portion to be paid | 30.00% | |||||||||
| Obligation to pay patent costs and annual license maintenance fees | 8,000 | |||||||||
| Milestone payment | 100,000 | 800,000 | ||||||||
| Expiry period of agreement of patented license | 20 years | |||||||||
| Range of each product line | 10 years | |||||||||
| Milestone payment due | 20,000,000 | 20,000,000 | ||||||||
| Period of milestone payment | 21 days | 21 days | ||||||||
| Reserve for contingency of non payment of non-royalty milestone amount | 20,000,000 | 20,000,000 | ||||||||
| Milestone payment made | 10,000,000 | 10,000,000 | ||||||||
| Balance amount of milestone payment | 10,000,000 | 10,000,000 | ||||||||
| Expiration of operating lease agreement | 2015-01 | |||||||||
| Expiration of non-cancellable operating lease agreement | 2017 | |||||||||
| Cash security deposit | 500,000 | |||||||||
| Standby letter of credit | 300,000 | |||||||||
| Lease liability | 3,717,000 | 3,906,000 | ||||||||
| Consolidated rent and facilities expense | 700,000 | 700,000 | ||||||||
| Indemnification obligations | 0 | |||||||||
| Expenses related to indemnification issues | $ 0 | |||||||||